Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
radiopharmaceutical
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06941480CT.gov A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 177lu-dtpa-sc16.56 (this asset) | Memorial Sloan Kettering Cancer Center | P1 | CC · 41 |
| Etoposide | National Cancer Institute (NCI) | P2 | B |
| Everolimus | AIO-Studien-gGmbH | P2 | B |
| Tarlatamab | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis Pharmaceuticals | P2 | B |
| Lurbinectedin | Jazz Pharmaceuticals | P2 | B |
| Pembrolizumab | Ochsner Health System | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Neuroendocrine Carcinoma cohort
Other indications for 177lu-dtpa-sc16.56
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Neuroendocrine Neoplasm | — | P1 | CC · 43 |
| Prostate Neuroendocrine Neoplasm | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideNational Cancer Institute (NCI)B
- EverolimusAIO-Studien-gGmbHB
- TarlatamabNational Cancer Institute (NCI)B
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)B
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Novartis PharmaceuticalsB
Citation
Floatz Terminal. 177lu-dtpa-sc16.56 in Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/177lu-dtpa-sc1656-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →